Bipolar Disorder – Global Drug Forecast and Market Analysis to 2030
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData estimated that drug sales for bipolar disorder in 2020 was valued at $4.1 billion across the eight major markets (8MM) – the US, the five major European markets (5EU) (France, Germany, Italy, Spain, and the UK), Japan, and Canada. It is anticipated that the bipolar disorder market will grow at a compound annual growth rate (CAGR) of more than 1.5% during the forecast period of 2021-2030.
The US market makes up the majority of total global sales, contributing to more than 80% due to the large bipolar disorder prevalent population, combined with the high price of medication in the country. Sumitomo Dainippon Pharma, along with its subsidiary Sunovion Pharmaceuticals, is one of the leading players in the bipolar disorder market and is expected to remain so during the forecast period.
Overview of the bipolar disorder drug market
For more insights on the report, download a free report sample
What are the market dynamics in the bipolar disorder drug market?
The major drivers of growth in the bipolar disorder market during the forecast period will include the following, seven new pipeline products will launch throughout the 8MM, and they will have significantly higher costs of therapy when compared with the cost of the most commonly used bipolar disorder treatments that have high generic availability. In the 8MM, the number of 12-month total prevalent cases of bipolar disorder is expected to increase during the forecast period.
The major barriers to growth in the bipolar disorder market during the forecast period will include the following, continued generic erosion is expected to further increase with the patent expiries of several key products, including Sumitomo Dainippon Pharma/ Sunovion Pharmaceuticals’ Latuda (lurasidone), Otsuka Pharmaceutical/Lundbeck’s Abilify Maintena (aripiprazole ER), and Johnson and Johnson’s Risperdal Consta (risperidone PR), during the forecast period. High use of inexpensive generic products, such as lithium, is expected to continue throughout the forecast period.
The misdiagnosis of bipolar disorder is common, and often results in patients receiving inappropriate pharmacological treatment and psychosocial support. Diagnosis rates for bipolar disorder are expected to remain low throughout the forecast period.
What are the diagnosed incident cases of bipolar disorder in the 8MM?
The 8MM include the US, Canada, France, Germany, Italy, Spain, UK, and Japan. In 2020, In 2020, the US accounted for more than 50% of the 12-month total prevalent cases of bipolar I disorder in the 8MM. There were more than 1,264,000 cases in the 5EU in 2020, of the 12-month total prevalent cases, while Japan had more than 1% cases and Canada had more than 6% cases of the total cases in 8MM. In the 8MM, the number of 12-month total prevalent cases of bipolar I disorder will grow by more than 4% over the forecast period at an Annual Growth Rate (AGR) of more than 0.40%. Of the 8MM, the US is expected to have 12-month total prevalent cases of bipolar I disorder increasing by 2030. Japan had the lowest number of 12-month total prevalent cases of bipolar I disorder in 2030. Any change in the 12-month total prevalent cases of bipolar I disorder is attributable to changing population demographics in the 8MM.
Diagnosed incident cases of bipolar disorder in the 8MM
For more regional insights, download a free report sample
Which are the key players in the bipolar disorder drug market?
Sumitomo Dainippon Pharma, along with its subsidiary Sunovion Pharmaceuticals, is one of the leading players in the bipolar disorder market and is expected to remain so during the forecast period. Other major players include AbbVie, Actavis, Alexza Pharmaceuticals, Alkermes, Allergan, AstraZeneca, BioXcel Therapeutics, Bristol-Myers Squibb, Celon Pharma, Eli Lilly, Intra-Cellular Therapies, Jina Pharmaceuticals, Johnson and Johnson, Lundbeck, Meiji Seika, Merck, NRX Pharmaceuticals, Otsuka Pharmaceutical, Pfizer, Richter Gedeon, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, and Vanda Pharmaceuticals.
Bipolar disorder drug market, by key players
For more insights on key players, download a free report sample
Market report scope
Market Size (Year – 2020) | $4.1 billion |
Growth rate (CAGR) | >1.5% |
Base Year | 2020 |
Forecast period | 2021-2030 |
Key Countries | The US, Canada, France, Germany, Italy, Spain, UK, and Japan |
Key Players | Sumitomo Dainippon Pharma, AbbVie, Actavis, Alexza Pharmaceuticals, Alkermes, Allergan, AstraZeneca, BioXcel Therapeutics, Bristol-Myers Squibb, Celon Pharma, Eli Lilly, Intra-Cellular Therapies, Jina Pharmaceuticals, Johnson and Johnson, Lundbeck, Meiji Seika, Merck, NRX Pharmaceuticals, Otsuka Pharmaceutical, Pfizer, Richter Gedeon, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, and Vanda Pharmaceuticals |
Scope
This report provides an in-depth analysis of the following:
- Overview of bipolar disorder, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized bipolar disorder therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (bipolar I, bipolar II and cyclothymic disorder) forecast from 2020 to 2030.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the bipolar disorder therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for bipolar disorder therapy. The most promising candidates in Phase III and IIb development are profiled.
- Analysis of the current and future market competition in the global bipolar disorder therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global bipolar disorder therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bipolar disorder therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Actavis
Alexza Pharmaceuticals
Alkermes
Allergan
AstraZeneca
BioXcel Therapeutics
Bristol-Myers Squibb
Celon Pharma
Eli Lilly
Intra-Cellular Therapies
Jina Pharmaceuticals
Johnson and Johnson
Lundbeck
Meiji Seika
Merck
NRX Pharmaceuticals
Otsuka Pharmaceutical
Pfizer
Richter Gedeon
Sumitomo Dainippon Pharma
Sunovion Pharmaceuticals
Vanda Pharmaceuticals
Table of Contents
Table
Figures
Frequently asked questions
-
What was the size of the bipolar disorder drug market in 2020?
The bipolar disorder drug market was valued at $4.1 billion in 2020 across the eight major markets (8MM).
-
What is the growth rate of the bipolar disorder drug market?
The bipolar disorder drug market will grow at a compound annual growth rate (CAGR) of more than 1.5% during the forecast period of 2021-2030.
-
Which country has the highest number of diagnosed incident cases of bipolar disorder?
In 2020, the US accounted for more than 50% of the diagnosed incident cases of bipolar disorder among the 8MM.
-
Who are the major players in the bipolar disorder drug market?
Sumitomo Dainippon Pharma, along with its subsidiary Sunovion Pharmaceuticals, is one of the leading players in the bipolar disorder market.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.